Asset / Drug

Venetoclax

Drug and asset intelligence for Venetoclax with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

AstraZeneca →

Recent signals(3)

ClinicalJune 21, 2026

Phase 1 Study of Venetoclax Combination in T-Cell Acute Lymphoblastic Leukemia

A Phase 1 study is underway evaluating a combination of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab in adolescents and young adults with relapsed or refractory T-ALL or T-LBL.

ClinicalJune 19, 2026

Phase III Trial of Early Treatment in High-Risk CLL/SLL Shows Promise

The EVOLVE CLL/SLL study is comparing early versus delayed treatment with venetoclax and obinutuzumab in high-risk CLL/SLL patients.

ClinicalJune 10, 2026

Phase II Trial of Venetoclax and Rituximab in Older Patients With Mantle Cell Lymphoma

A Phase II trial is underway to evaluate the efficacy of venetoclax combined with rituximab in older patients with untreated mantle cell lymphoma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Venetoclax

Follow the trial's progress and results, particularly any efficacy and safety data that emerge from this Phase 1 study.

June 21, 2026 · N/A

Topline Data

AstraZeneca — Venetoclax

Monitor the trial's progress and results for overall response rates and any updates on patient outcomes.

June 10, 2026 · N/A

Indications

Mantle Cell Lymphoma →

T-Cell Acute Lymphoblastic Leukemia →

Therapeutic areas

Mantle Cell Lymphoma →

Oncology →

Oncology · Mantle Cell Lymphoma →

Oncology · T-Cell Acute Lymphoblastic Leukemia →

T-Cell Acute Lymphoblastic Leukemia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.